C.I.N.B.O.

The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 >= 50% advanced non-small-cell lung cancer.

Banna GL, Cortellini A, Cortinovis DL, Tiseo M, Aerts JGJV, Barbieri F, Giusti R, Bria E, Grossi F, Pizzutilo P, Berardi R, Morabito A, Genova C, Mazzoni F, Di Noia V, Signorelli D, Gelibter A, Macerelli M, Rastelli F, Chiari R, Rocco D, Gori S, De Tursi M, Di Marino P, Mansueto G, Zoratto F, Filetti M, Montrone M, Citarella F, Marco R, Cantini L, Nigro O, D'Argento E, Buti S, Minuti G, Landi L, Guaitoli G, Lo Russo G, De Toma A, Donisi C, Friedlaender A, De Giglio A, Metro G, Porzio G, Ficorella C, Addeo A

ESMO Open. 2021-03-15. 2021 Mar 15;6(2):100078. doi: 10.1016/j.esmoop.2021.100078. LEGGI...

Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case-control matched analysis from a large multicenter study

Cortellini A, De Giglio A, Cannita K, Cortinovis DL, Cornelissen R, Baldessari C, Giusti R, D'Argento E, Grossi F, Santoni M, Catino A, Berardi R, Sforza V, Rossi G, Antonuzzo L, Di Noia V, Signorelli D, Gelibter A, Occhipinti MA, Follador A, Rastelli F, Chiari R, Gravara LD, Inno A, De Tursi M, Di Marino P, Mansueto G, Zoratto F, Filetti M, Montrone M, Citarella F, Pensieri MV, Russano M, Cantini L, Nigro O, Leonetti A, Bordi P, Minuti G, Landi L, De Toma A, Donisi C, Ricciardi S, Migliorino MR, Napoli VM, Leone G, Metro G, Banna GL, Friedlaender A, Addeo A, Ficorella C, Porzio G

Thorac Cancer. 2021-03-15. 2021 Mar;12(6):880-889. doi: 10.1111/1759-7714.13852. LEGGI...

Phenotypic and Proteomic Analysis Identifies Hallmarks of Blood Circulating Extracellular Vesicles in NSCLC Responders to Immune Checkpoint Inhibitors

Brocco D, Lanuti P, Pieragostino D, Cufaro MC, Simeone P, Bologna G, Di Marino P, De Tursi M, Grassadonia A, Irtelli L, De Lellis L, Veschi S, Florio R, Federici L, Marchisio M, Miscia S, Cama A, Tinari N, Del Boccio P

Cancers (Basel). 2021-02-03. 2021 Feb 3;13(4):585. doi: 10.3390/cancers13040585. LEGGI...

Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index

Buti S, Bersanelli M, Perrone F, Tiseo M, Tucci M, Adamo V, Stucci LS, Russo A, Tanda ET, Spagnolo F, Rastelli F, Pergolesi F, Santini D, Russano M, Anesi C, Giusti R, Filetti M, Marchetti P, Botticelli A, Gelibter A, Occhipinti MA, Ferrari M, Vitale MG, Nicolardi L, Chiari R, Rijavec E, Nigro O, Tuzi A, De Tursi M, Di Marino P, Conforti F, Queirolo P, Bracarda S, Macrini S, Gori S, Zoratto F, Veltri E, Di Cocco B, Mallardo D, Vitale MG, Santoni M, Patruno L, Porzio G, Ficorella C, Pinato DJ, Ascierto PA, Cortellini A

Eur J Cancer. 2021-01-15. 2021 Jan;142:18-28. doi: 10.1016/j.ejca.2020.09.033. LEGGI...

The Management of Dental Practices in the Post-COVID 19 Era: An Economic and Operational Perspective.

Lo Nigro G, Bizzoca ME, Lo Muzio L, Campisi G

Int J Environ Res Public Health. 2020-11-30. 2020 Nov 30;17(23):8905. doi: 10.3390/ijerph17238905. LEGGI...

Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of >=50

Cortellini A, Tiseo M, Banna GL, Cappuzzo F, Aerts JGJV, Barbieri F, Giusti R, Bria E, Cortinovis D, Grossi F, Migliorino MR, Galetta D, Passiglia F, Santini D, Berardi R, Morabito A, Genova C, Mazzoni F, Di Noia V, Signorelli D, Tuzi A, Gelibter A, Marchetti P, Macerelli M, Rastelli F, Chiari R, Rocco D, Gori S, De Tursi M, Mansueto G, Zoratto F, Santoni M, Tudini M, Rijavec E, Filetti M, Catino A, Pizzutilo P, Sala L, Citarella F, Marco R, Torniai M, Cantini L, Targato G, Sforza V, Nigro O, Ferrara MG, D'Argento E, Buti S, Bordi P, Antonuzzo L, Scodes S, Landi L, Guaitoli G, Baldessari C, Della Gravara L, Dal Bello MG, Belderbos RA, Bironzo P, Carnio S, Ricciardi S, Grieco A, De Toma A, Proto C, Friedlaender A, Cantale O, Ricciuti B, Addeo A, Metro G, Ficorella C, Porzio G

Cancer ImmunolImmunother. 2020-11-15. 2020 Nov;69(11):2209-2221. doi: 10.1007/s00262-020-02613-9. LEGGI...

Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice

Cortellini A, Tucci M, Adamo V, Stucci LS, Russo A, Tanda ET, Spagnolo F, Rastelli F, Bisonni R, Santini D, Russano M, Anesi C, Giusti R, Filetti M, Marchetti P, Botticelli A, Gelibter A, Occhipinti MA, Marconcini R, Vitale MG, Nicolardi L, Chiari R, Bareggi C, Nigro O, Tuzi A, De Tursi M, Petragnani N, Pala L, Bracarda S, Macrini S, Inno A, Zoratto F, Veltri E, Di Cocco B, Mallardo D, Vitale MG, Pinato DJ, Porzio G, Ficorella C, Ascierto PA

J Immunother Cancer. 2020-11-15. 2020 Nov;8(2):e001361. doi: 10.1136/jitc-2020-001361. LEGGI...

An innovative risk-scoring system of dental procedures and safety protocols in the COVID-19 era

Bizzoca ME, Campisi G, Lo Muzio L

BMC OralHealth. 2020-11-04. 2020 Nov 4;20(1):301. doi: 10.1186/s12903-020-01301-5. LEGGI...

Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ? 50%: a multicenter study with external validation.

Cortellini A, Ricciuti B, Tiseo M, Bria E, Banna GL, Aerts JG, Barbieri F, Giusti R, Cortinovis DL, Migliorino MR, Catino A, Passiglia F, Torniai M, Morabito A, Genova C, Mazzoni F, Di Noia V, Signorelli D, Gelibter A, Occhipinti MA, Rastelli F, Chiari R, Rocco D, Inno A, De Tursi M, Di Marino P, Mansueto G, Zoratto F, Grossi F, Filetti M, Pizzutilo P, Russano M, Citarella F, Cantini L, Targato G, Nigro O, Ferrara MG, Buti S, Scodes S, Landi L, Guaitoli G, Della Gravara L, Tabbo' F, Ricciardi S, De Toma A, Friedlaender A, Petrelli F, Addeo A, Porzio G, Ficorella C

J Immunother Cancer. 2020-10-15. 2020 Oct;8(2):e001403. doi: 10.1136/jitc-2020-001403. LEGGI...

FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules

Foschini F, Napolitano F, Servetto A, Marciano R, Mozzillo E, Carratu' AC, Santaniello A, De Placido P, Cascetta P, Butturini G, Frigerio I, Regi P, Silvestris N, Delcuratolo S, Vasile E, Vivaldi C, Bianco C, De Placido S, Formisano L, Bianco R

TherAdvMedOncol. 2020-09-29. 2020 Sep 29;12:1758835920947970. doi: 10.1177/1758835920947970. LEGGI...

Leukoplakia and Immunology: New Chemoprevention Landscapes?

Grigolato R, Bizzoca ME, Calabrese L, Leuci S, Mignogna MD, Lo Muzio L

Int J Mol Sci. 2020-09-19. 2020 Sep 19;21(18):6874. doi: 10.3390/ijms21186874. LEGGI...

Raccomandazioni clinico-terapeutiche sull'osteonecrosi delle ossa mascellari (ONJ) farmaco-relata e sua prevenzione

Giuseppina Campisi, Alberto Bedogni, Vittorio Fusco

Versione 2.0 / 2020 SICMF - Societa' Italiana di Chirurgia Maxillo-Facciale SIPMO - Societa' di Patologia e Medicina Orale. 2020-07-15. . LEGGI...

Predictive Ability for Disease-Free Survival of the GRade, Age, Nodes, and Tumor (GRANT) Score in Patients with Resected Renal Cell Carcinoma

Cortellini A, Buti S, Bersanelli M, Cannita K, Pinterpe G, Venditti O, Verna L, Porzio G, Natoli C, Tinari N, Cindolo L, Di Clemente L, Grassadonia A, De Tursi M, Ficorella C

CurrUrol. 2020-06-15. 2020 Jun;14(2):98-104. doi: 10.1159/000499252. LEGGI...

Alectinib Induced Regression of Renal and Hepatic Cysts Caused by Crizotinib.

Di Marino P, Mannetta G, Carella C, Grassadonia A, Tinari N, Natoli C, De Tursi M.

Int Med Case Rep J.. 2020-03-16. 2020 Mar 16; 13:89-93. doi: 10.2147/IMCRJ.S229080.. LEGGI...

Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events.

Cortellini A, Bersanelli M, Santini D, Buti S, Tiseo M, Cannita K, Perrone F, Giusti R, De Tursi M, Zoratto F, Marconcini R, Russano M, Zeppola T, Anesi C, Filetti M, Marchetti P, Botticelli A, Gelibter A, De Galitiis F, Vitale MG, Rastelli F, Tudini M, Silva RR, Atzori F, Chiari R, Ricciuti B, De Giglio A, Migliorino MR, Mallardo D, Vanella V, Mosillo C, Bracarda S, Rinaldi S, Berardi R, Natoli C, Ficorella C, Porzio G, Ascierto PA.

Eur J Cancer. 2020-03-15. 2020 Mar; 128:17-26. doi: 10.1016/j.ejca.2019.12.031. Epub 2020 Mar 5.. LEGGI...

Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study.

Cortellini A, Bozzetti F, Palumbo P, Brocco D, Di Marino P, Tinari N, De Tursi M, Agostinelli V, Patruno L, Valdesi C, Mereu M, Verna L, Lanfiuti Baldi P, Venditti O, Cannita K, Masciocchi C, Barile A, McQuade JL, Ficorella C, Porzio G.

Sci Rep.. 2020-01-29. 2020 Jan 29;10(1):1456. doi: 10.1038/s41598-020-58498-2.. LEGGI...

Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study.

Cortellini A, Buti S, Bersanelli M, Giusti R, Perrone F, Di Marino P, Tinari N, De Tursi M, Grassadonia A, Cannita K, Tessitore A, Zoratto F, Veltri E, Malorgio F, Russano M, Anesi C, Zeppola T, Filetti M, Marchetti P, Botticelli A, Cappellini GCA, De Galitiis F, Vitale MG, Rastelli F, Pergolesi F, Berardi R, Rinaldi S, Tudini M, Silva RR, Pireddu A, Atzori F, Iacono D, Migliorino MR, Gelibter A, Occhipinti MA, Martella F, Inno A, Gori S, Bracarda S, Zannori C, Mosillo C, Parisi A, Porzio G, Mallardo D, Fargnoli MC, Tiseo M, Santini D, Ascierto PA, Ficorella C.

Oncoimmunology.. 2020-01-07. 2020 Jan 7;9(1):1710389. doi: 10.1080/2162402X.2019.1710389.. LEGGI...

Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation

D. Brocco, P. Lanuti, P. Simeone, G. Bologna, D. Pieragostino, M. C. Cufaro, V. Graziano, M. Peri, P. Di Marino, M. De Tursi, I. G. Rapposelli, L. Pierdomenico, E. Ercolino, F. Ciccocioppo, P. Del Boccio, M. Marchisio, C. Natoli, S. Miscia, and N. Tinari

J Oncol.. 2019-11-18. 2019; 2019: 5879616. Published online 2019 Nov 18. doi: 10.1155/2019/5879616. LEGGI...

Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: a retrospective multicenter study.

Grassadonia A, Di Marino P, Ficorella C, Cortellini A, Cannita K, Parisi A, Gamucci T, Zoratto F, Vici P, Barba M, Porreca E, Neri M, Veronese A, Natoli C, De Tursi M, Tinari N.

J Cancer.. 2019-10-15. 2019 Oct 15;10(24):5926-5934. doi: 10.7150/jca.34550.. LEGGI...

Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC).

Incorvaia L, Fanale D, Badalamenti G, Barraco N, Bono M, Corsini LR, Galvano A, Gristina V, Listi' A, Vieni S, Gori S, Bazan V, Russo A.

Adv Ther.. 2019-10-15. 2019 Oct;36(10):2600-2617. doi: 10.1007/s12325-019-01057-7.. LEGGI...

Impact of BMI on clinical outcome in advanced cancer patients treated with anti-PD-1 Immune checkpoint inhibitors: a preliminary analysis

Alessio Cortellini, Michele De Tursi, Nicola Tinari, Antonino Grassadonia, Alessandro Parisi, Laura Iezzi, Pietro Di Marino, Nicola D'Ostilio, Davide Brocco, Melissa Bersanelli, Marta Peri, Katia Cannita, Corrado Ficorella and Clara Natoli

Journal of Translational Medicine. 2019-07-15. 2019, 17(Supp 1):12 doi: 10.1186/s12967-018-1745-7. LEGGI...

A Case of Stage I Vulvar Squamous Cell Carcinoma with Early Relapse and Rapid Disease Progression.

Peri M, Grassadonia A, Iezzi L, Vici P, De Tursi M, Natoli C, Tinari N, Zilli M.

Case Rep Oncol Med.. 2019-07-03. 2019 Jul 3; 2019:1018492. doi: 10.1155/2019/1018492.. LEGGI...

Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in patients with metastatic melanoma?

Lorena Incorvaia, Giuseppe Badalamenti, Gaetana Rinaldi, Juan Lucio Iovanna, Daniel Olive, Mirna Swayden, Lidia Terruso, Bruno Vincenzi, Fabio Fulfaro, Viviana Bazan, Antonio Russo, and Daniele Fanale

Ther Adv Med Oncol.. 2019-05-15. 2019; 11: 1758835919848872. doi: 10.1177/1758835919848872. LEGGI...

Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario

Alessandro Russo, Tindara Franchina, Giuseppina Ricciardi, Alessandra Battaglia, Maria Picciotto and Vincenzo Adamo

Int. J. Mol. Sci.. 2019-03-21. 2019, 20(6), 1431; https://doi.org/10.3390/ijms20061431 . LEGGI...

A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable.

Cortellini A, Bersanelli M, Buti S, Cannita K, Santini D, Perrone F, Giusti R, Tiseo M, Michiara M, Di Marino P, Tinari N, De Tursi M, Zoratto F, Veltri E, Marconcini R, Malorgio F, Russano M, Anesi C, Zeppola T, Filetti M, Marchetti P, Botticelli A, Antonini Cappellini GC, De Galitiis F, Vitale MG, Rastelli F, Pergolesi F, Berardi R, Rinaldi S, Tudini M, Silva RR, Pireddu A, Atzori F, Chiari R, Ricciuti B, De Giglio A, Iacono D, Gelibter A, Occhipinti MA, Parisi A, Porzio G, Fargnoli MC, Ascierto PA, Ficorella C, Natoli C.

J Immunother Cancer.. 2019-02-27. 2019 Feb 27;7(1):57. doi: 10.1186/s40425-019-0527-y.. LEGGI...

Nectin-4 and p63 immunohistochemical expression in canine prostate tumourigenesis.

Della Salda L, Massimini M, Romanucci M, Palmieri C, Perillo A, Grieco V, Malatesta D, Spinillo MA, Passantino G, Dondi F, Benazzi C.

Vet Comp Oncol.. 2019-02-15. 2019 Feb 15. doi: 10.1111/vco.12469. [Epub ahead of print]. LEGGI...

Predictive value of skeletal muscle mass for immunotherapy with nivolumab in non-small cell lung cancer patients: A "hypothesis-generator" preliminary report.

Cortellini A, Verna L, Porzio G, Bozzetti F, Palumbo P, Masciocchi C, Cannita K, Parisi A, Brocco D, Tinari N, Ficorella C.

Thorac Cancer.. 2019-02-10. 2019 Feb;10(2):347-351. doi: 10.1111/1759-7714.12965.. LEGGI...

Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients.

Graziano V, Grassadonia A, Iezzi L, Vici P, Pizzuti L, Barba M, Quinzii A, Camplese A, Di Marino P, Peri M, Veschi S, Alberti S, Gamucci T, Di Gioacchino M, De Tursi M, Natoli C, Tinari N.

Breast.. 2019-01-02. 2019 Jan 2;44:33-38. doi: 10.1016/j.breast.2018.12.014.. LEGGI...

Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials.

Grassadonia A, Sperduti I, Vici P, Iezzi L, Brocco D, Gamucci T, Pizzuti L, Maugeri-Sacca' M, Marchetti P, Cognetti G, De Tursi M, Natoli C, Barba M, Tinari N.

J Clin Med.. 2018-12-12. 2018 Dec 12;7(12). pii: E542. doi: 10.3390/jcm7120542.. LEGGI...

Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience.

Pizzuti L, Giordano A, Michelotti A, Mazzotta M, Natoli C, Gamucci T, De Angelis C, Landucci E, Diodati L, Iezzi L, Mentuccia L, Fabbri A, Barba M, Sanguineti G, Marchetti P, Tomao S, Mariani L, Paris I, Lorusso V, Vallarelli S, Cassano A, Airoldi F, Orlandi A, Moscetti L, Sergi D, Sarobba MG, Tonini G, Santini D, Sini V, Veltri E, Vaccaro A, Ferrari L, De Tursi M, Tinari N, Grassadonia A, Greco F, Botticelli A, La Verde N, Zamagni C, Rubino D, Cortesi E, Magri V, Pomati G, Scagnoli S, Capomolla E, Kayal R, Scinto AF, Corsi D, Cazzaniga M, Laudadio L, Forciniti S, Mancini M, Carbognin L, Seminara P, Barni S, Samaritani R, Roselli M, Portarena I, Russo A, Ficorella C, Cannita K, Carpano S, Pistelli M, Berardi R, De Maria R, Sperduti I, Ciliberto G, Vici P.

J Cell Physiol.. 2018-12-10. 2018 Dec 10. doi: 10.1002/jcp.27832.. LEGGI...

The changing scenario of 1st line therapy in non-oncogene addicted NSCLCs in the era of immunotherapy.

Russo A, Franchina T, Ricciardi GRR, Toscano G, Schifano S, Lo Certo G, Battaglia A, Panto' E, Scaffidi Fonti M, Adamo V.

Crit Rev Oncol Hematol.. 2018-10-15. 2018 Oct;130:1-12. doi: 10.1016/j.critrevonc.2018.06.007. LEGGI...

Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel.

Russo A, Franchina T, Ricciardi GRR, Battaglia A, Scimone A, Berenato R, Giordano A, Adamo V.

J Cell Physiol.. 2018-10-14. 2018 Oct;233(10):6337-6343. doi: 10.1002/jcp.26609.. LEGGI...

Challenges with anti-PD1 agents in brain metastases management of NSCLC patients: a case report

Russo A, Franchina T, Ricciardi GRR, Battaglia A, Scimone A, Adamo V.

APMB - Atti della Accademia Peloritana dei Pericolanti Classe di Scienze Medico Biologiche.. 2018-05-15. 2018; 106 (1): A6 (1-9).. LEGGI...

Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting.

Gamucci T, Pizzuti L, Sperduti I, Mentuccia L, Vaccaro A, Moscetti L, Marchetti P, Carbognin L, Michelotti A, Iezzi L, Cassano A, Grassadonia A, Astone A, Botticelli A, Magnolfi E, Di Lauro L, Sergi D, Fuso P, Tinari N, Barba M, Maugeri-Sacca' M, Landucci E, Conti F, Sanguineti G, De Tursi M, Iafrate G, Giordano A, Ciliberto G, Natoli C, Vici P.

J Cell Physiol. 2018-03-01. 2018 Mar;233(3):2313-2323. doi: 10.1002/jcp.26103. LEGGI...

Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy - a case report and literature review.

Ricciardi GRR, Russo A, Franchina T, Schifano S, Mastroeni G, Santacaterina A, Adamo V.

BMC Cancer. 2018-01-25. 2018 Jan 25;18(1):97. doi: 10.1186/s12885-018-3994-5. LEGGI...

Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy - a case report and literature review.

Ricciardi GRR, Russo A, Franchina T, Schifano S, Mastroeni G, Santacaterina A, Adamo V.

BMC Cancer.. 2018-01-25. 2018 Jan 25;18(1):97. doi: 10.1186/s12885-018-3994-5.. LEGGI...

Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going.

Russo A, Franchina T, Ricciardi GRR, Smiroldo V, Picciotto M, Zanghi' M, Rolfo C, Adamo V.

Crit Rev OncolHematol. 2017-09-01. 2017 Sep;117:38-47. doi: 10.1016/j.critrevonc.2017.07.003. LEGGI...

The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer.

Adamo B, Rita Ricciardi GR, Ieni A, Franchina T, Fazzari C, Sano' MV, Angelico G, Michele C, Tuccari G, Adamo V.

Oncotarget. 2017-08-16. 2017 Aug 16;8(44):76974-76986. doi: 10.18632/oncotarget.20293. eCollection 2017 Sep 29.. LEGGI...

Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting.

J Cell Physiol. 2017-07-15. 2017 Jul 15. doi: 10.1002/jcp.26103.. LEGGI...

Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going.

Russo A, Franchina T, Ricciardi GRR, Smiroldo V, Picciotto M, Zanghi' M, Rolfo C, Adamo V.

Crit Rev OncolHematol. 2017-07-05. 2017 Sep;117:38-47. doi: 10.1016/j.critrevonc.2017.07.003. Epub 2017 Jul 5.. LEGGI...

A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer.

Gamucci T, Mentuccia L, Natoli C, Sperduti I, Cassano A, Michelotti A, Di Lauro L, Sergi D, Fabi A, Sarobba MG, Marchetti P, Barba M, Magnolfi E, Maugeri-Sacca' M, Rossi E, Sini V, Grassadonia A, Pellegrini D, Astone A, Nistico' C, Angelini F, Vaccaro A, Pellegrino A, De Angelis C, Palleschi M, Moscetti L, Bertolini I, Buglioni S, Giordano A, Pizzuti L, Vici P.

J Cell Physiol. 2017-06-15. 2017 Jun;232(6):1571-1578. doi: 10.1002/jcp.25685. Epub 2016 Nov 30. LEGGI...

Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer.

Picciotto M, Franchina T, Russo A, Ricciardi GRR, Provazza G, Sava S, Baldari S, Caffo O, Adamo V.

Expert OpinPharmacother. 2017-06-15. 2017 Jun;18(9):899-908. doi: 10.1080/14656566.2017.1323875. Epub 2017 May 8.. LEGGI...

A retrospective multicentric observational study of trastuzumabemtansine in HER2 positive metastatic breast cancer: a real-world experience.

Vici P, Pizzuti L, Michelotti A, Sperduti I, Natoli C, Mentuccia L, Di Lauro L, Sergi D, Marchetti P, Santini D, Magnolfi E, Iezzi L, Moscetti L, Fabbri A, Cassano A, Grassadonia A, Omarini C, Piacentini F, Botticelli A, Bertolini I, Scinto AF, Zampa G, Mauri M, D'Onofrio L, Sini V, Barba M, Maugeri-Sacca' M, Rossi E, Landucci E, Tomao S, Alberti AM, Giotta F, Ficorella C, Adamo V, Russo A, Lorusso V, Cannita K, Barni S, Laudadio L, Greco F, Garrone O, Della Giulia M, Marolla P, Sanguineti G, Di Cocco B, Ciliberto G, De Maria R, Gamucci T.

Oncotarget. 2017-05-25. 2017 May 25;8(34):56921-56931. doi: 10.18632/oncotarget.18176. eCollection 2017 Aug 22.. LEGGI...

Anthropometric, clinical and molecular determinants of treatment outcomes in postmenopausal, hormone receptor positive metastatic breast cancer patients treated with fulvestrant: Results from a real word setting.

Pizzuti L, Natoli C, Gamucci T, Mauri M, Sergi D, Di Lauro L, Paoletti G, Ruggeri E, Iezzi L, Sperduti I, Mentuccia L, Fabbri A, Maugeri-Sacca' M, Moscetti L, Barba M, Vici P.

Oncotarget. 2017-04-09. 2017 Apr 9;8(40):69025-69037. doi: 10.18632/oncotarget.16982. LEGGI...

'Back to a false normality': new intriguing mechanisms of resistance to PARP inhibitors.

Incorvaia L, Passiglia F, Rizzo S, Galvano A, Listi' A, Barraco N, Maragliano R, Calo' V, Natoli C, Ciaccio M, Bazan V, Russo A.

Oncotarget. 2017-04-04. 2017 Apr 4;8(14):23891-23904. doi: 10.18632/oncotarget.14409. Review. LEGGI...

Long-term outcome of breast cancer patients with pathologic N3a lymph node stage

Grassadonia A, Vici P, Gamucci T, Moscetti L, Pizzuti L, Mentuccia L, Iezzi L, Scognamiglio MT, Zilli M, Giampietro J, Graziano V, Natoli C, Tinari N.

Breast. 2017-04-01. 2017 Apr;32:79-86. doi: 10.1016/j.breast.2016.12.018. LEGGI...

Body mass index modifies the relationship between ?-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer.

Barba M, Vici P, Pizzuti L, Di Lauro L, Sergi D, Di Benedetto A, Ercolani C, Sperati F, Terrenato I, Botti C, Mentuccia L, Iezzi L, Gamucci T, Natoli C, Vitale I, Mottolese M, De Maria R, Maugeri-Sacca' M.

BMC Cancer. 2017-02-06. 2017 Feb 6;17(1):101. doi: 10.1186/s12885-016-3045-z.. LEGGI...

Influence of EGFR mutational status on metastatic behavior in non squamous non small cell lung cancer.

Russo A, Franchina T, Ricciardi GR, Fanizza C, Scimone A, Chiofalo G, Giordano A, Adamo V.

Oncotarget. 2017-01-31. 2017 Jan 31;8(5):8717-8725. doi: 10.18632/oncotarget.14427. LEGGI...

Influence of EGFR mutational status on metastatic behavior in non squamousnon small cell lung cancer.

Russo A, Franchina T, Ricciardi GR, Fanizza C, Scimone A, Chiofalo G, Giordano A, Adamo V.

Oncotarget. 2017-01-31. 2017 Jan 31;8(5):8717-8725. doi: 10.18632/oncotarget.14427. LEGGI...

Long-term outcome of breast cancer patients with pathologic N3a lymph node stage.

Grassadonia A, Vici P, Gamucci T, Moscetti L, Pizzuti L, Mentuccia L, Iezzi L, Scognamiglio MT, Zilli M, Giampietro J, Graziano V, Natoli C, Tinari N.

Breast. 2016-12-18. 2017 Jan 5;32:79-86. doi: 10.1016/j.breast.2016.12.018. LEGGI...

Neoadjuvant Sequential Docetaxel Followed by High-Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial.

Pizzuti L, Barba M, Giannarelli D, Sergi D, Botti C, Marchetti P, Anza' M, Maugeri-Sacca' M, Natoli C, Di Filippo S, Catenaro T, Tomao F, Amodio A, Carpano S, Perracchio L, Mottolese M, Di Lauro L, Sanguineti G, Di Benedetto A, Giordano A, Vici P.

J Cell Physiol. 2016-11-15. 2016 Nov;231(11):2541-7. doi: 10.1002/jcp.25432. LEGGI...

A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer

J Cell Physiol. 2016-11-11. 2016 Nov 11. doi: 10.1002/jcp.25685. LEGGI...

Long time response with chemotherapy in ROS1 NSCLC patient with unusual metastatic site.

Franchina T, Russo A, Ricciardi GR, Liguori G, Herberg A, Normanno N, Adamo V.

Cancer BiolTher. 2016-08-12. 2016 Aug 12:1-5. LEGGI...

The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?

Bronte G, Incorvaia L, Rizzo S, Passiglia F, Galvano A, Rizzo F, Rolfo C, Fanale D, Listi' A, Natoli C, Bazan V, Russo A.

Crit Rev OncolHematol. 2016-08-11. 2016 Nov;107:20-32. doi: 10.1016/j.critrevonc.2016.08.011. LEGGI...

Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance.

Russo A, Franchina T, Ricciardi GR, Ferraro G, Scimone A, Bronte G, Russo A, Rolfo C, Adamo V.

Expert Rev Anticancer Ther. 2016-06-15. 2016 Jun;16(6):615-23. doi: 10.1080/14737140.2016.1182427. Epub 2016 May 10.. LEGGI...

Topographic expression of the Hippo transducers TAZ and YAP in triple-negative breast cancer treated with neoadjuvant chemotherapy.

Vici P, Ercolani C, Di Benedetto A, Pizzuti L, Di Lauro L, Sperati F, Terrenato I, Gamucci T, Natoli C, Di Filippo F, Botti C, Barba M, Mottolese M, De Maria R, Maugeri-Sacca' M

J ExpClinCancer Res. 2016-04-02. 35(1):62. doi: 10.1186/s13046-016-0338-7. LEGGI...

The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status

Bronte G, Franchina T, Alu' M, Sortino G, Celesia C, Passiglia F, Savio G, Laudani A, Russo A, Picone A, Rizzo S, De Tursi M, Gambale E, Bazan V, Natoli C, Blasi L, Adamo V, Russo A

Oncotarget. 2016-03-16. doi: 10.18632/oncotarget.8130. [Epubahead of print]. LEGGI...

PD-L1 expression as predictive biomarker in patients with NSCLC: a pooledanalysis

Passiglia F, Bronte G, Bazan V, Natoli C, Rizzo S, Galvano A, Listi' A, Cicero G, Rolfo C, Santini D, Russo A.

Oncotarget. 2016-02-22. doi: 10.18632/oncotarget.7582. LEGGI...

"Triple positive" early breast cancer: an observational multicenter retrospective analysis of outcome

Vici P, Pizzuti L, Sperduti I, Frassoldati A, Natoli C, Gamucci T, Tomao S, Michelotti A, Moscetti L, Gori S, Baldini E, Giotta F, Cassano A, Santini D, Giannarelli D, Di Lauro L, Corsi DC, Marchetti P, Sini V, Sergi D, Barba M, Maugeri-Sacca' M, Russillo M, Mentuccia L, D'Onofrio L, Iezzi L, Scinto AF, Da Ros L, Bartolini I, Basile ML, Rossi V, De Maria R, Montemurro F.

Oncotarget. 2016-02-18. doi: 10.18632/oncotarget.7480. LEGGI...

Beyond evidence-based data: scientific rationale and tumorbehavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma

Incorvaia L, Bronte G, Bazan V, Badalamenti G, Rizzo S, Pantuso G, Natoli C, Russo A.

Oncotarget. 2016-02-08. doi: 10.18632/oncotarget.7267. LEGGI...

Predictive significance of DNA damage and repair biomarkers in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: An exploratory analysis

Vici P, Di Benedetto A, Ercolani C, Pizzuti L, Di Lauro L, Sergi D, Sperati F, Terrenato I, Dattilo R, Botti C, Fabi A, Ramieri MT, Mentuccia L, Marinelli C, Iezzi L, Gamucci T, Natoli C, Vitale I, Barba M, Mottolese M, De Maria R, Maugeri-Sacca' M.

Oncotarget. 2015-12-15. 6(40):42773-80. doi: 10.18632/oncotarget.6001. LEGGI...

Is the skin a sanctuary for breast cancer cells during treatment with anti-HER2 antibodies?

Graziano V, Scognamiglio MT, Zilli M, Giampietro J, Vici P, Natoli C, Grassadonia A.

Cancer Biol Ther. 2015-11-09. [Epubahead of print]. LEGGI...

What links BRAF to the heartfunction? new insights from the cardiotoxicity of BRAF inhibitors in cancer treatment.

Bronte E, Bronte G, Novo G, Bronte F, Bavetta MG, Lo Re G, Brancatelli G, Bazan V, Natoli C, Novo S, Russo A.

Oncotarget. 2015-11-03. 6(34):35589-601. doi: 10.18632/oncotarget.5853. LEGGI...

Predictive significance of DNA damage and repair biomarkers in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: An exploratory analysis.

Oncotarget. 2015-10-17. doi: 10.18632/oncotarget.6001. [Epubahead of print]. LEGGI...

Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients.

Vincenzi B, Cremolini C, Sartore-Bianchi A, Russo A, Mannavola F, Perrone G, Pantano F, Loupakis F, Rossini D, Ongaro E, Bonazzina E, Dell'Aquila E, Imperatori M, Zoccoli A, Bronte G, De Maglio G, Fontanini G, Natoli C, Falcone A, Santini D, Onetti-Muda A, Siena S, Tonini G, Aprile G.

Oncotarget. 2015-10-13. 6(31):31604-12. doi: 10.18632/oncotarget.5231. LEGGI...

A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives.

Russo A, Franchina T, Ricciardi GR, Picone A, Ferraro G, Zanghi' M, Toscano G, Giordano A, Adamo V.

Oncotarget. 2015-09-29. 2015 Sep 29;6(29):26814-25. doi: 10.18632/oncotarget.4254. LEGGI...

Effect of targeted agents on the endocrine response of breast cancer in the neoadjuvant setting: a systematic review.

Grassadonia A, Caporale M, Tinari N, Zilli M, DeTursi M, Gamucci T, Vici P, Natoli C.

J Cancer. 2015-05-12. 6(6):575-82. doi: 10.7150/jca.11566. eCollection 2015. LEGGI...

Identification of subgroups of early breast cancer patients at high risk of nonadherence to adjuvant hormone therapy: results of an Italian survey.

Tinari N, Fanizza C, Romero M, Gambale E, Moscetti L, Vaccaro A, Seminara P, Longo F, Gori S, Vici P, Gamucci T, Mauri M, Laudadio L, Nuzzo A, Fabbri MA, Fattoruso SI, Mazzilli L, Grassadonia A, Cianchetti E, Natoli C.

Clin Breast Cancer. 2015-04-15. e131-7. doi: 10.1016/j.clbc.2014.10.005. Epub 2014 Oct 22. LEGGI...

Endothelin A receptor/Beta-arrestin signaling to the Wnt pathway renders ovarian cancer cells resistant to chemotherapy.

Rosano' L, Cianfrocca R, Tocci P, Spinella F, Di Castro V, Caprara V, Semprucci E, Ferrandina G, Natali PG, Bagnato A

Cancer Res. 2014-12-15. 74(24):7453-64. doi: 10.1158/0008-5472.CAN-13-3133. Epub 2014 Nov 6. LEGGI...

Chemotherapy-induced nausea and vomiting in Italian cancer centers: results of CINVDAY, a prospective, multicenter study.

Tumori. 2014-11-15. 100(6):e309-13. doi: 10.1700/1778.19310. LEGGI...

Membranous Nectin-4 expressionis a risk factor for distant relapse of T1-T2, N0 luminal-A early breast cancer.

Oncogenesis. 2014-09-01. 3:e118. doi: 10.1038/oncsis.2014.32. LEGGI...

High nuclear level of Vav1 is a positive prognostic factor in early invasive breast tumors: a role in modulating genes related to the efficiency of metastatic process

Grassilli S, Brugnoli F, Lattanzio R, Rossi C, Perracchio L, Mottolese M, Marchisio M, Palomba M, Nika E, Natali PG, Piantelli M, Capitani S, Bertagnolo V

Oncotarget. 2014-06-30. 5(12):4320-36.. LEGGI...

Breast cancer "tailored follow-up" in Italian oncology units: a web-based survey.

Natoli C, Brocco D, Sperduti I, Nuzzo A, Tinari N, De Tursi M, Grassadonia A, Mazzilli L, Iacobelli S, Gamucci T, Vici P; 'FOLLOW-UP' Study Group

PLoSOne. 2014-04-08. 8;9(4):e94063. doi: 10.1371/journal.pone.0094063. eCollection 2014. LEGGI...

EV20, a Novel Anti-ErbB-3 Humanized Antibody, Promotes ErbB-3 Down-Regulation and Inhibits Tumor Growth In Vivo

Sala G, Rapposelli IG, Ghasemi R, Piccolo E, Traini S, Capone E, Rossi C, Pelliccia A, Di Risio A, D'Egidio M, Tinari N, Muraro R, Iacobelli S; Consorzio Interuniversitario Nazionale per la Bio-Oncologia (CINBO)

Transl Oncol. 2013-12-01. 6(6):676-84. eCollection 2013 Dec 1. LEGGI...

Overexpression of activated phospholipase Cgamma1 is a risk factor for distant metastases in T1-T2, N0 breast cancer patients undergoing adjuvant chemotherapy

Lattanzio R, Marchisio M, La Sorda R, Tinari N, Falasca M, Alberti S, Miscia S, Ercolani C, Di Benedetto A, Perracchio L, Melucci E, Iacobelli S, Mottolese M, Natali PG, Piantelli M; CINBO(Consorzio Interuniversitario Nazionale per Bio-Oncologia).

Int J Cancer. 2013-03-01. 132(5):1022-31. doi: 10.1002/ijc.27751. Epub 2012 Sep 1. LEGGI...

Beta-arrestin-1 is a nuclear transcriptional regulator of endothelin-1-induced Beta-cateninsignaling

Rosano' L, Cianfrocca R, Tocci P, Spinella F, Di Castro V, Spadaro F, Salvati E, Biroccio AM, Natali PG, Bagnato A.

Oncogene. 2012-12-03. doi: 10.1038/onc.2012.527. [Epubahead of print]. LEGGI...

LMNA knock-down affects differentiation and progression of human neuroblastoma cells

Maresca G, Natoli M, Nardella M, Arisi I, Trisciuoglio D, Desideri M, Brandi R, D�Aguanno S, Nicotra MR, D�Onofrio M, Urbani A, Natali PG, Del Bufalo D, Felsani A, D�Agnano I

PLoSOne. 2012-09-26. 7(9):e45513. doi: 10.1371/journal.pone.0045513. Epub 2012 Sep 26. LEGGI...

Endothelin-1 induces the transactivation of vascular endothelial growth factor receptor-3 and modulates cell migration and vasculogenic mimicry in melanoma cells

Spinella F, Caprara V, Di Castro V, Rosano' L, Cianfrocca R, Natali PG, Bagnato A.

J Mol Med (Berl). 2012-09-11. [Epubahead of print]. LEGGI...

Overexpression of activated phospholipase Cgamma1 is a risk factor for distant metastases in T1-T2, N0 breast cancer patients undergoing adjuvant chemotherapy

Lattanzio R, Marchisio M, La Sorda R, Tinari N, Falasca M, Alberti S, Miscia S, Ercolani C, Di Benedetto A, Perracchio L, Melucci E, Iacobelli S, Mottolese M, Natali PG, Piantelli M; on behalf of CINBO (Consorzio Interuniversitario Nazionale per la Bio-Oncologia).

Int J Cancer. 2012-07-31. doi: 10.1002/ijc.27751. [Epubahead of print]. LEGGI...

Melanoma molecular classes and prognosis in the postgenomic era

Tremante E, Ginebri A, Lo Monaco E, Frascione P, Di Filippo F, Terrenato I, Benevolo M, Mottolese M, Pescarmona E, Visca P, Natali PG, Giacomini P.

Lancet Oncol. 2012-05-13. 13(5):e205-11. doi: 10.1016/S1470-2045(12)70003-7. LEGGI...

An ErbB-3 antibody, MP-RM-1, inhibits tumor growth by blocking ligand-dependent and independent activation of ErbB-3/Ak tsignaling

Sala G, Traini S, D'Egidio M, Vianale G, Rossi C, Piccolo E, Lattanzio R, Piantelli M, Tinari N, Natali PG, Muraro R, Iacobelli S; Consorzio Interuniversitario Nazionale per la Bio-Oncologia

Oncogene. 2012-03-08. 31(10):1275-86. doi: 10.1038/onc.2011.322. Epub 2011 Aug 8. LEGGI...

Cell-to-cell signaling influences the fate of prostate cancer stem cells and their potential to generate more aggressive tumors

Salvatori L, Caporuscio F, Verdina A, Starace G, Crispi S, Nicotra MR, Russo A, Calogero RA, Morgante E, Natali PG, Russo MA, Petrangeli E.

PLoSOne. 2012-02-06. 7(2):e31467. doi: 10.1371/journal.pone.0031467. Epub 2012 Feb 6. LEGGI...

Meta-analysis of phase III trials of docetaxel alone or in combination with chemotherapy in metastaticb reastcancer

Belfiglio M, Fanizza C, Tinari N, Ficorella C, Iacobelli S, Natoli C; Consorzio Interuniversitario Nazionale per la Bio-Oncologia (CINBO)

J Cancer Res Clin Oncol. 2011-11-18. 2012 Feb;138(2):221-9. doi: 10.1007/s00432-011-1091-0. Epub 2011 Nov 18. LEGGI...

Fucans, but not fucomanno glucuronans, determine the biological activities of sulfated polysaccharides from Laminaria saccharina brown seaweed

Croci DO, Cumashi A, Ushakova NA, Preobrazhenskaya ME, Piccoli A, Totani L, Ustyuzhanina NE, Bilan MI, Usov AI, Grachev AA, Morozevich GE, Berman AE, Sanderson CJ, Kelly M, Di Gregorio P, Rossi C, Tinari N, Iacobelli S, Rabinovich GA, Nifantiev NE; Consorzio Interuniversitario Nazionale per la Bio-Oncologia (CINBO),Italy

PLoSOne. 2011-02-28. 6(2):e17283. doi: 10.1371/journal.pone.0017283. LEGGI...

Tyrosine kinase inhibitors

Natoli C, Perrucci B, Perrotti F, Falchi L, Iacobelli S; Consorzio Interuniversitario Nazionale per Bio-Oncologia (CINBO)

Curr Cancer Drug Targets. 2010-08-01. 10(5):462-83. LEGGI...

Triplet schedule of weekly 5-fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: a dose-finding and phase II study

Morelli MF, Santomaggio A, Ricevuto E, Cannita K, De Galitiis F, Tudini M, Bruera G, Mancini M, Pelliccione M, Calista F, Guglielmi F, Martella F, Lanfiuti Baldi P, Porzio G, Russo A, Gebbia N, Iacobelli S, Marchetti P, Ficorella C.

Oncol Rep. 2010-06-01. 23(6):1635-40. LEGGI...

Relations betweenstrain and gender dependencies of irinotecan toxicity and UGT1A1, CES2 and TOP1 expressions in mice

Ahowesso C, Piccolo E, Li XM, Dulong S, Hossard V, La Sorda R, Filipski E, Tinari N, Delaunay F, Iacobelli S, Levi F.

Toxicol Lett. 2010-02-15. 192(3):395-401. Epub 2009 Nov 29. LEGGI...

Synthetic inhibitors of galectin-1 and -3 selectively modulate homotypic cell aggregation and tumor cell apoptosis

Iurisci I, Cumashi A, Sherman AA, Tsvetkov YE, Tinari N, Piccolo E, D'Egidio M, Adamo V, Natoli C, Rabinovich GA, Iacobelli S, Nifantiev NE; Consorzio Interuniversitario Nazionale Per la Bio-Oncologia

Anticancer Res. 2009-01-29. 29(1):403-10. LEGGI...

High expression of 90K (Mac-2 BP) isassociated with poors urvival in node-negative breast cancer patients no treceiving adjuvant systemic therapies

Tinari N, Lattanzio R, Querzoli P, Natoli C, Grassadonia A, Alberti S, Hubalek M, Reimer D, Nenci I, Bruzzi P, Piantelli M, Iacobelli S; Consorzio Interuniversitario Nazionale per la Bio-Oncologia (CINBO)

Molecular mechanisms of endocrine resistance and their implication in the therapy of breast cancer

Zilli M, Grassadonia A, Tinari N, Di Giacobbe A, Gildetti S, Giampietro J, Natoli C, Iacobelli S; Consorzio Interuniversitario Nazionale per la Bio-Oncologia (CINBO)

Biochim Biophys Acta. 2008-08-29. 1795(1):62-81. Epub 2008 Aug 29. LEGGI...

Upstream stimulatory factor regulates constitutive expression and hormonal suppression of the 90K (Mac-2BP) protein

Grassadonia A, Tinari N, Fiorentino B, Nakazato M, Chung HK, Giuliani C, Napolitano G, Iacobelli S, Howcroft TK, Singer DS, Kohn LD; Consorzio Interuniversitario Nazionale per la Bioncologia.

Endocrinology. 2007-04-19. 148(7):3507-17. Epub 2007 Apr 19. LEGGI...

A comparative study of the anti-inflammatory, anticoagulant, antiangiogenic, and anti adhesive activities of nine different fucoidans from brown sea weeds

Cumashi A, Ushakova NA, Preobrazhenskaya ME, D'Incecco A, Piccoli A, Totani L, Tinari N, Morozevich GE, Berman AE, Bilan MI, Usov AI, Ustyuzhanina NE, Grachev AA, Sanderson CJ, Kelly M, Rabinovich GA, Iacobelli S, Nifantiev NE; Consorzio Interuniversitario Nazionale per la Bio-Oncologia, Italy

Glycobiology. 2007-02-12. 17(5):541-52. Epub 2007 Feb 12. LEGGI...

Novel P53 mutations detected by FAMA in colorectal cancers

De Galitiis F, Cannita K, Tessitore A, Martella F, Di Rocco ZC, Russo A, Adamo V, Iacobelli S, Martinotti S, Marchetti P, Ficorella C, Ricevuto E; Consorzio Interuniversitario Nazionale Bio-Oncologia.

Ann Oncol.. 2006-06-01. 17 Suppl 7:vii78-83. LEGGI...

Changes of topoisomerase II alpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival

Tinari N, Lattanzio R, Natoli C, Cianchetti E, Angelucci D, Ricevuto E, Ficorella C, Marchetti P, Alberti S, Piantelli M, Iacobelli S

Clin Cancer Res. 2006-03-01. 12(5):1501-6. LEGGI...

Pubblicazioni